Guerbet announces US Food and Drug Administration approval of Elucirem


Guerbet announced that the US Food and Drug Administration (FDA), after priority review, has approved Elucirem (Gadopiclenol), a new macrocyclic gadolinium-based contrast agent (GBCA) for use in contrast-enhanced magnetic resonance imaging (MRI).

Elucirem (Gadopiclenol) is a new macrocyclic GBCA with high relaxivity indicated for use in adults and children aged two years and older, for contrast-enhanced magnetic resonance imaging (MRI). The product is used to detect and visualise lesions with abnormal vascularity in the central nervous system and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).

Gadopiclenol, the active substance of Elucirem, has been designed with two sites for water molecule exchange to increase relaxivity and contrast, allowing it to be used at half the conventional dose of gadolinium compared to other non-specific GBCAs.

The efficacy and safety of Gadopiclenol have been assessed as part of Guerbet’s clinical development plan, with marketing authorisation being targeted worldwide (cf. phase III trial results below).

The FDA is the first health authority to have approved Elucirem. It is currently in the process of examination by the European Medicines Agency via a centralised procedure.

“As a pioneer in MR imaging, thanks to the success of our first gadolinium-based macrocyclic contrast agent, we are delighted with the FDA approval of Elucirem. This approval allows patients and practitioners to benefit from the innovations brought by Elucirem,” said David Hale, chief executive officer of Guerbet Group.

Phase III clinical trials for Elucirem

The approval was primarily based on data from two phase III studies completed in March 2021 which demonstrated that Elucirem leads to non-inferior results in brain and body MRI at half the gadolinium dose of Gadobutrol. The endpoints were met in terms of the diagnostic benefit of injecting Gadopiclenol (0.05 mmol/kg) during MRI examinations, based on two criteria:

  • The superiority of the examination with Gadopiclenol compared to the examination with no contrast agent
  • The non-inferiority of Gadopiclenol (0.05 mmol/kg) compared to Gadobutrol (0.1 mmol/kg) for the visualisation and detection of lesions of the central nervous system and in the other anatomical areas studied

No major safety signals were reported during the development of Gadopiclenol, and the adverse reactions reported during the two phase III studies were similar for both products administered.


Please enter your comment!
Please enter your name here